Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05544929 · ClinicalTrials.gov registry record · Phase 1

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

A Phase 1 study of Carcinoma, Non-Small Cell Lung and Mesothelioma, sponsored by Novartis Pharmaceuticals.

Active
Registry status
Phase 1
Development phase
126
Enrollment target
19
Study locations

NCT05544929 is a Phase 1 study of Carcinoma, Non-Small Cell Lung and Mesothelioma that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 126 participants, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (61% lower). The trial reports 19 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05544929, a Phase 1 study of Carcinoma, Non-Small Cell Lung and Mesothelioma, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
126 participants
Enrollment target
19
Study locations

Study Summary

The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.

Conditions Studied

Carcinoma, Non-Small Cell Lung Mesothelioma Carcinoma, Renal Cell Cutaneous Melanoma Anal Cancer Nasopharyngeal Carcinoma Esophagogastric Cancer Carcinoma, Ovarian Epithelial Carcinoma, Thymic High Microsatellite Instability Colorectal Carcinoma

Interventions

  • DRUG pembrolizumab
  • DRUG KFA115

Study Locations (19)

Other

  • Novartis Investigative Site - Beijing
  • Novartis Investigative Site - Lyon
  • Novartis Investigative Site - Essen
  • Novartis Investigative Site - Hong Kong
  • Novartis Investigative Site - Singapore
  • Novartis Investigative Site - Seoul
  • Novartis Investigative Site - Taipei

Massachusetts

  • Massachusetts General Hospital . - Boston
  • Massachusetts General Hospital - Boston

New York

  • NYU School of Medicine - New York

Pennsylvania

  • University of Pittsburgh Medical Center - Pittsburgh

Tennessee

  • SCRI Oncology Partners - Nashville

Ontario

  • Novartis Investigative Site - Toronto

Guangdong

  • Novartis Investigative Site - Guangzhou

Saxony

  • Novartis Investigative Site - Dresden

Trial Details

FieldValue
Enrollment Target 126 participants
Start Date 2022-10-26
Est. Completion 2027-09-01
Phase Phase 1

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05544929

The ClinicalTrials.gov registry entry for NCT05544929 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 323-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (61% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which pembrolizumab is the first listed.

NCT05544929 reports 19 study locations spanning 12 distinct geographic areas - top geographies include Other, Massachusetts, New York.

Frequently Asked Questions

What is clinical trial NCT05544929 about?

NCT05544929 is a clinical study titled "A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers". The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.

What is the current status of trial NCT05544929?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2022-10-26. Estimated completion is 2027-09-01.

What conditions does trial NCT05544929 study?

This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung, Mesothelioma, Carcinoma, Renal Cell, Cutaneous Melanoma, Anal Cancer.

What interventions are being tested in trial NCT05544929?

The interventions under investigation include: pembrolizumab (DRUG), KFA115 (DRUG).

Who is sponsoring clinical trial NCT05544929?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05544929 being conducted?

This trial has 19 study locations across Massachusetts, New York, Pennsylvania, Tennessee, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Non-Small Cell Lung

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Non-Small Cell Lung

All registered trials for this condition

Mesothelioma

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.